<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Genmab A/s — News on 6ix</title>
<link>https://6ix.com/company/genmab-as-1</link>
<description>Latest news and press releases for Genmab A/s on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 08 May 2026 19:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/genmab-as-1" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d51a67beedb30cb6f6563f.webp</url>
<title>Genmab A/s</title>
<link>https://6ix.com/company/genmab-as-1</link>
</image>
<item>
<title>Major Shareholder Announcement</title>
<link>https://6ix.com/company/genmab-as-1/news/major-shareholder-announcement-21</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as-1/news/major-shareholder-announcement-21</guid>
<pubDate>Fri, 08 May 2026 19:05:00 GMT</pubDate>
<description>Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; May 8, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that through shares, as of May 8, 2026, Orbis Investment Management Limited controlled the voting rights to 3,166,357 shares in Genmab A/S, which amounts to 5.08% of the share capital and voting rights in Genmab A/S. The major shareholder an</description>
</item>
<item>
<title>Genmab Announces Financial Results for the First Quarter of 2026</title>
<link>https://6ix.com/company/genmab-as-1/news/genmab-announces-financial-results-for-the-first-quarter-of-2026</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as-1/news/genmab-announces-financial-results-for-the-first-quarter-of-2026</guid>
<pubDate>Thu, 07 May 2026 15:02:00 GMT</pubDate>
<description>May 7, 2026 Copenhagen, Denmark; Interim Report for the Three Months Ended March 31, 2026 Highlights Genmab revenue increased 25% compared to the first three months of 2025, to $896 millionFDA approved an sBLA to remove the recommendation for 24-hour hospitalization for patients with third line plus relapsed/refractory DLBCL Remained focused on disciplined investment in our late-stage portfolio, EPKINLY® (epcoritamab), Rina-S®, and petosemtamab, including launch readiness “We made tangible progr</description>
</item>
<item>
<title>Genmab A/S Share Capital Reduction</title>
<link>https://6ix.com/company/genmab-as-1/news/genmab-as-share-capital-reduction</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as-1/news/genmab-as-share-capital-reduction</guid>
<pubDate>Fri, 17 Apr 2026 14:56:00 GMT</pubDate>
<description>Company Announcement COPENHAGEN, Denmark; April 17, 2026 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S’ Annual General Meeting on March 19, 2026, it was decided to reduce the Company’s share capital with nominally DKK 1,900,000 by cancellation of 1,900,000 of the Company’s holding of shares with a nominal value of DKK 1 each. The share capital reduction has today been registered with the Danish Business Authority. Genmab's share capital will be updated in Nasdaq's system as soon as possible and expe</description>
</item>
<item>
<title>Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026</title>
<link>https://6ix.com/company/genmab-as-1/news/genmab-announces-net-sales-of-darzalexr-daratumumab-for-first-quarter-of-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as-1/news/genmab-announces-net-sales-of-darzalexr-daratumumab-for-first-quarter-of-2026-1</guid>
<pubDate>Tue, 14 Apr 2026 10:23:00 GMT</pubDate>
<description>Company Announcement Net sales of DARZALEX® in the first quarter of 2026 totaled USD 3,964 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; April 14, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as repor</description>
</item>
<item>
<title>Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer</title>
<link>https://6ix.com/company/genmab-as-1/news/genmab-presents-the-safety-and-tolerability-of-rinatabart-sesutecan-rina-sr-in-combination-with-bevacizumab-in-advanced-ovarian-cancer-1</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as-1/news/genmab-presents-the-safety-and-tolerability-of-rinatabart-sesutecan-rina-sr-in-combination-with-bevacizumab-in-advanced-ovarian-cancer-1</guid>
<pubDate>Mon, 13 Apr 2026 13:35:00 GMT</pubDate>
<description>COPENHAGEN, Denmark, April 13, 2026--Genmab A/S (Nasdaq: GMAB) announced today new data demonstrating that rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), evaluated in combination with bevacizumab in patients with advanced ovarian cancer, showed a safety profile consistent with the known safety profiles of Rina-S and bevacizumab. These data are from the combination therapy cohort D2 of the m</description>
</item>
<item>
<title>Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons</title>
<link>https://6ix.com/company/genmab-as-1/news/transactions-with-shares-and-linked-securities-in-genmab-as-made-by-managerial-employees-and-their-closely-associated-persons</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as-1/news/transactions-with-shares-and-linked-securities-in-genmab-as-made-by-managerial-employees-and-their-closely-associated-persons</guid>
<pubDate>Wed, 01 Apr 2026 19:19:00 GMT</pubDate>
<description>Company Announcement COPENHAGEN, Denmark; April 1, 2026 – Genmab A/S (Nasdaq: GMAB) - This document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse, Genmab A/S publishes transactions in shares and linked securities issued by Genmab A/S by managerial employees and their closely associated persons. The transactions concern vesting of restri</description>
</item>
<item>
<title>Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab</title>
<link>https://6ix.com/company/genmab-as-1/news/constitution-of-the-board-of-directors-in-genmab-as-and-grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as-1/news/constitution-of-the-board-of-directors-in-genmab-as-and-grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab</guid>
<pubDate>Thu, 19 Mar 2026 18:21:00 GMT</pubDate>
<description>Company AnnouncementCOPENHAGEN, Denmark; March 19, 2026 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 19, 2026, the Company’s Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant 5,213 restricted stock units and 4,485 warrants to the employees of the Company and the Company’s subsidiaries.Each restricted stock unit is awarded cost-free and pr</description>
</item>
<item>
<title>Passing of Genmab A/S’ Annual General Meeting</title>
<link>https://6ix.com/company/genmab-as-1/news/passing-of-genmab-as-annual-general-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as-1/news/passing-of-genmab-as-annual-general-meeting</guid>
<pubDate>Thu, 19 Mar 2026 14:06:00 GMT</pubDate>
<description>Company Announcement At Genmab A/S’ Annual General Meeting held today March 19, 2026, the Annual Report for 2025 was approvedDischarge was given to the Board of Directors and the Executive Management and the year’s profit was carried forwardThe 2025 Compensation Report was approvedSix members of the Board of Directors were re-electedDeloitte was re-elected as the auditor of the CompanyThe proposal from the Board of Directors to reduce the Company’s share capital with nominally DKK 1,900,000 by c</description>
</item>
<item>
<title>Completion of Share Buy-back Program</title>
<link>https://6ix.com/company/genmab-as-1/news/completion-of-share-buy-back-program</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as-1/news/completion-of-share-buy-back-program</guid>
<pubDate>Mon, 16 Mar 2026 14:09:00 GMT</pubDate>
<description>Company Announcement COPENHAGEN, Denmark; March 16, 2026 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 13, 2026. On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum aggregate total value of 725 million DKK to honor our commitments under the Restricted Stock Unit program. The share buy-back program was expected to be completed no later than March 31, 2026. The follow</description>
</item>
<item>
<title>Transactions in Connection with Share Buy-back Program</title>
<link>https://6ix.com/company/genmab-as-1/news/transactions-in-connection-with-share-buy-back-program</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as-1/news/transactions-in-connection-with-share-buy-back-program</guid>
<pubDate>Mon, 09 Mar 2026 14:01:00 GMT</pubDate>
<description>Company Announcement COPENHAGEN, Denmark; March 9, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum aggregate total value of DKK 725 million to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than March 31, 2026. The following transactions were executed under the program from March 2 to March 6, 2026: N</description>
</item>
<item>
<title>Correction to Company Announcement No. 13 of March 2, 2026</title>
<link>https://6ix.com/company/genmab-as-1/news/correction-to-company-announcement-no-13-of-march-2-2026</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as-1/news/correction-to-company-announcement-no-13-of-march-2-2026</guid>
<pubDate>Mon, 02 Mar 2026 21:53:00 GMT</pubDate>
<description>Company Announcement COPENHAGEN, Denmark; March 2, 2026 – Genmab A/S (Nasdaq: GMAB) - Correction: In Company Announcement no. 13/2026 regarding transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons it was reported that the share price associated with these transactions was DKK 0,00. The correct price is DKK 1,867.50. In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/52</description>
</item>
<item>
<title>Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab</title>
<link>https://6ix.com/company/genmab-as-1/news/grant-of-restricted-stock-units-to-management-and-employees-and-grant-of-warrants-to-employees-in-genmab</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as-1/news/grant-of-restricted-stock-units-to-management-and-employees-and-grant-of-warrants-to-employees-in-genmab</guid>
<pubDate>Fri, 27 Feb 2026 20:21:00 GMT</pubDate>
<description>Company Announcement COPENHAGEN, Denmark; February 27, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 587,495 restricted stock units to members of management and employees of the Company as well as the Company's subsidiaries and 455,004 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK</description>
</item>
<item>
<title>Genmab to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/genmab-as-1/news/genmab-to-participate-in-upcoming-investor-conferences-1</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as-1/news/genmab-to-participate-in-upcoming-investor-conferences-1</guid>
<pubDate>Wed, 25 Feb 2026 15:27:00 GMT</pubDate>
<description>Media ReleaseCOPENHAGEN, Denmark; February 25, 2026Genmab A/S (Nasdaq: GMAB) announced today that members of its Executive Committee will participate in fireside chats at the following investor conferences in March 2026: TD Cowen 46th Annual Healthcare Conference in Boston on March 3, 2026, 9:10 AM EST (3:10 PM CET)Leerink Global Healthcare Conference in Miami on March 10, 2026, 8:40 AM EDT (1:40 PM CET)Barclays 28th Annual Global Healthcare Conference in Miami on March 11, 2026, 1:30 PM EDT (6:</description>
</item>
<item>
<title>Capital Increase in Genmab as a Result of Employee Warrant Exercise</title>
<link>https://6ix.com/company/genmab-as-1/news/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as-1/news/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise</guid>
<pubDate>Tue, 24 Feb 2026 20:20:00 GMT</pubDate>
<description>Company Announcement COPENHAGEN, Denmark; February 24, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 12,313 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 710 shares at DKK 1,147.50,239 shares at DKK 1,155.00,1,527 shares at DKK 1,161.00,1,183 shares at DKK 1,334.5</description>
</item>
<item>
<title>Notice to Convene the Annual General Meeting of Genmab A/S</title>
<link>https://6ix.com/company/genmab-as-1/news/notice-to-convene-the-annual-general-meeting-of-genmab-as</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as-1/news/notice-to-convene-the-annual-general-meeting-of-genmab-as</guid>
<pubDate>Wed, 18 Feb 2026 14:09:00 GMT</pubDate>
<description>Company Announcement Genmab A/S to hold Annual General Meeting on Thursday March 19, 2026 COPENHAGEN, Denmark; February 18, 2026 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Thursday, March 19, 2026, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, DK-1560 Copenhagen V, Denmark. The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors, is attached. About Genmab Genmab is an international biotechnology company d</description>
</item>
<item>
<title>Genmab Announces Initiation of Share Buy-Back Program</title>
<link>https://6ix.com/company/genmab-as-1/news/genmab-announces-initiation-of-share-buy-back-program</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as-1/news/genmab-announces-initiation-of-share-buy-back-program</guid>
<pubDate>Tue, 17 Feb 2026 20:14:00 GMT</pubDate>
<description>Company Announcement Repurchase of up to 342,130 shares with a maximum aggregate total value of 725 million DKK Honoring our commitments under the Restricted Stock Unit programCompletion expected no later than March 31, 2026 COPENHAGEN, Denmark; February 17, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that it is initiating a share buy-back program, to honor our commitments under the Restricted Stock Unit program. The share buy-back program will be undertaken on the terms set out below and i</description>
</item>
<item>
<title>Genmab Files Annual Report with the U.S. Securities and Exchange Commission</title>
<link>https://6ix.com/company/genmab-as-1/news/genmab-files-annual-report-with-the-us-securities-and-exchange-commission</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as-1/news/genmab-files-annual-report-with-the-us-securities-and-exchange-commission</guid>
<pubDate>Tue, 17 Feb 2026 16:23:00 GMT</pubDate>
<description>Media ReleaseCOPENHAGEN, Denmark; February 17, 2026 Genmab filed Form 20-F for the financial year 2025 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial year 2025 on Form 20-F with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Genmab A/S Annual Report 2025. Both reports are available via the SEC’s website, www.sec.gov and Genmab’s website, www.genmab.com. About Genmab Genmab is an interna</description>
</item>
<item>
<title>Genmab Publishes 2025 Annual Report</title>
<link>https://6ix.com/company/genmab-as-1/news/genmab-publishes-2025-annual-report-1</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as-1/news/genmab-publishes-2025-annual-report-1</guid>
<pubDate>Tue, 17 Feb 2026 16:01:00 GMT</pubDate>
<description>Company Announcement COPENHAGEN, Denmark; February 17, 2026 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2025. Below is a summary of business progress in 2025, financial performance for the year and the financial outlook for 2026. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of the company’s website, www.genmab.com/investor-relations. Conference CallGenmab will hold a conference call to discuss the</description>
</item>
<item>
<title>Grant of Restricted Stock Units and Warrants to Employees in Genmab</title>
<link>https://6ix.com/company/genmab-as-1/news/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as-1/news/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab</guid>
<pubDate>Thu, 29 Jan 2026 17:49:00 GMT</pubDate>
<description>Company Announcement COPENHAGEN, Denmark; January 29, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 32,806 restricted stock units and 34,307 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the da</description>
</item>
<item>
<title>Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025</title>
<link>https://6ix.com/company/genmab-as-1/news/genmab-announces-net-sales-of-darzalexr-daratumumab-for-2025</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as-1/news/genmab-announces-net-sales-of-darzalexr-daratumumab-for-2025</guid>
<pubDate>Wed, 21 Jan 2026 11:23:00 GMT</pubDate>
<description>Company Announcement Net sales of DARZALEX® in 2025 totaled USD 14,351 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; January 21, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were U</description>
</item>
</channel>
</rss>